Aethlon Medical Inc. (AEMD)
NASDAQ: AEMD
· Real-Time Price · USD
1.14
-0.03 (-2.56%)
At close: Aug 15, 2025, 3:50 PM
Company Description
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States.
The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes.
Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer.
The company was founded in 1999 and is based in San Diego, California.
Aethlon Medical Inc.
| Country | United States |
| IPO Date | Mar 4, 1999 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 14 |
| CEO | James B. Frakes |
Contact Details
Address: 11555 Sorrento Valley Road San Diego, California United States | |
| Website | https://www.aethlonmedical.com |
Stock Details
| Ticker Symbol | AEMD |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0000882291 |
| CUSIP Number | 00808Y505 |
| ISIN Number | US00808Y5050 |
| Employer ID | 13-3632859 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| James B. Frakes M.B.A. | Chief Executive Officer, Chief Financial Officer, Secretary & Director |
| Guy F. Cipriani BS (Eng.), MBA | Senior Vice President & Chief Operating Officer |
| Dr. Steven P. LaRosa M.D. | Chief Medical Officer |
| Michele Bombardiere | Vice President & Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Aug 13, 2025 | 10-Q | Quarterly Report |
| Aug 13, 2025 | 8-K | Current Report |
| Jul 01, 2025 | 4 | Filing |
| Jul 01, 2025 | 4 | Filing |
| Jul 01, 2025 | 4 | Filing |
| Jun 27, 2025 | 8-K | Current Report |
| Jun 26, 2025 | 10-K | Annual Report |
| Jun 05, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G | Filing |